Rixubis यूरोपीय संघ - फ़िनिश - EMA (European Medicines Agency)

rixubis

baxalta innovations gmbh - nonacog gamma - hemofilia b - hemostaatit - verenvuodon hoito ja ehkäisy potilailla, joilla on hemofilia b (synnynnäinen tekijä ix -häiriö).

LEFLUNOMIDE STADA 10 mg tabletti, kalvopäällysteinen फ़िनलैंड - फ़िनिश - Fimea (Suomen lääkevirasto)

leflunomide stada 10 mg tabletti, kalvopäällysteinen

stada arzneimittel ag - leflunomidum - tabletti, kalvopäällysteinen - 10 mg - leflunomidi

Leflunomide Stada 20 mg tabletti, kalvopäällysteinen फ़िनलैंड - फ़िनिश - Fimea (Suomen lääkevirasto)

leflunomide stada 20 mg tabletti, kalvopäällysteinen

stada arzneimittel ag - leflunomide - tabletti, kalvopäällysteinen - 20 mg - leflunomidi

Teriflunomide Sandoz 14 mg tabletti, kalvopäällysteinen फ़िनलैंड - फ़िनिश - Fimea (Suomen lääkevirasto)

teriflunomide sandoz 14 mg tabletti, kalvopäällysteinen

sandoz a/s - teriflunomide - tabletti, kalvopäällysteinen - 14 mg - teriflunomidi

Teriflunomide Krka 14 mg tabletti, kalvopäällysteinen फ़िनलैंड - फ़िनिश - Fimea (Suomen lääkevirasto)

teriflunomide krka 14 mg tabletti, kalvopäällysteinen

krka, d.d., novo mesto - teriflunomide - tabletti, kalvopäällysteinen - 14 mg - teriflunomidi

Teriflunomide Avansor 14 mg tabletti, kalvopäällysteinen फ़िनलैंड - फ़िनिश - Fimea (Suomen lääkevirasto)

teriflunomide avansor 14 mg tabletti, kalvopäällysteinen

avansor pharma oy - teriflunomide - tabletti, kalvopäällysteinen - 14 mg - teriflunomidi

Teriflunomide Orion 14 mg tabletti, kalvopäällysteinen फ़िनलैंड - फ़िनिश - Fimea (Suomen lääkevirasto)

teriflunomide orion 14 mg tabletti, kalvopäällysteinen

orion corporation - teriflunomide - tabletti, kalvopäällysteinen - 14 mg - teriflunomidi

BeneFIX यूरोपीय संघ - फ़िनिश - EMA (European Medicines Agency)

benefix

pfizer europe ma eeig - nonacog alfa - hemofilia b - hemostaatit - verenvuodon hoito ja ehkäisy hemofilia b-potilailla (synnynnäinen tekijä ix: n vajaus).

Raplixa यूरोपीय संघ - फ़िनिश - EMA (European Medicines Agency)

raplixa

mallinckrodt pharmaceuticals ireland limited - ihmisen fibrinogeeni, ihmisen trombiini - hemostaasi, kirurginen - hemostaatit - tukihoito, jossa tavanomaiset leikkaustekniikat ovat riittämättömiä hemostaasin parantamiseksi. raplixa on käytettävä yhdessä hyväksytyn liivate sienellä. raplixa on tarkoitettu aikuisille yli 18-vuotiaille.

Comirnaty यूरोपीय संघ - फ़िनिश - EMA (European Medicines Agency)

comirnaty

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - rokotteet - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. käyttö tämä rokote tulee virallisten suositusten mukaisesti.